Edwards Lifesciences Corporation $EW Shares Bought by Swiss National Bank

Swiss National Bank lifted its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 6.6% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 1,773,100 shares of the medical research company’s stock after buying an additional 109,600 shares during the quarter. Swiss National Bank’s holdings in Edwards Lifesciences were worth $138,674,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Rosenberg Matthew Hamilton bought a new position in Edwards Lifesciences in the second quarter worth about $28,000. Quantbot Technologies LP acquired a new stake in shares of Edwards Lifesciences during the 1st quarter worth approximately $26,000. NewSquare Capital LLC increased its position in Edwards Lifesciences by 57.8% in the second quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock worth $29,000 after buying an additional 134 shares during the period. SouthState Corp acquired a new stake in Edwards Lifesciences in the first quarter worth $27,000. Finally, Costello Asset Management INC bought a new stake in Edwards Lifesciences in the first quarter valued at $29,000. Institutional investors own 79.46% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently commented on EW. Daiwa America upgraded shares of Edwards Lifesciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 29th. Wall Street Zen downgraded Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a research report on Monday, September 29th. JPMorgan Chase & Co. raised their price objective on shares of Edwards Lifesciences from $85.00 to $90.00 and gave the company a “neutral” rating in a research note on Friday, October 31st. UBS Group restated a “neutral” rating and issued a $90.00 target price on shares of Edwards Lifesciences in a research report on Monday, November 3rd. Finally, William Blair raised Edwards Lifesciences to a “strong-buy” rating in a research note on Friday, July 25th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Edwards Lifesciences has an average rating of “Moderate Buy” and a consensus price target of $91.39.

Edwards Lifesciences Price Performance

EW opened at $85.02 on Friday. The firm has a market capitalization of $49.34 billion, a P/E ratio of 12.23, a PEG ratio of 3.97 and a beta of 1.03. The stock has a fifty day moving average of $78.80 and a 200-day moving average of $78.04. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 12-month low of $65.94 and a 12-month high of $87.21.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.59 by $0.08. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The firm had revenue of $1.55 billion during the quarter, compared to analyst estimates of $1.49 billion. During the same period last year, the company posted $0.67 EPS. The business’s quarterly revenue was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. Equities analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,020 shares of Edwards Lifesciences stock in a transaction on Monday, November 10th. The shares were sold at an average price of $82.55, for a total transaction of $84,201.00. Following the completion of the sale, the vice president owned 22,002 shares of the company’s stock, valued at $1,816,265.10. This trade represents a 4.43% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Scott B. Ullem sold 13,000 shares of the business’s stock in a transaction on Monday, November 10th. The shares were sold at an average price of $83.08, for a total transaction of $1,080,040.00. Following the transaction, the chief financial officer owned 39,898 shares in the company, valued at approximately $3,314,725.84. This represents a 24.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.